ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
98 050,57
0,30%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. NRX Pharmaceuticals Inc (NRXP) Cours

NRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc (NRXP)

NASDAQ
1,50
-0,02
(-1,32%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes
1,52
0,02
(1,33%)
Après les heures de négociation: 1:56AM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
1,52
Prix Achat
1,45
Prix Vente
1,52
Volume échangé
380 130
1,46 Fourchette du Jour 1,55
1,10 Plage de 52 semaines 7,333
Cap du marché
18,383M
Clôture Veille
1,52
Ouverture
1,55
Dernière Transaction
3
@
1.52
Dernière heure de transaction
Volume financier
US$ 571 941
VWAP
1,5046
Volume moyen (3 m)
191 811
Actions en circulation
12 094 094
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,61
Bénéfice par action (BPA)
-2,49
Chiffre d'affairess
-
Bénéfice net
-30,16M

À propos de NRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-... NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. Show more

Secteur
Pharmaceutical Preparations
Industrie
Blank Checks
Site Web
www.nrxpharma.com
Siège social
Wilmington, Delaware, USA
Fondé
2021
NRX Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker NRXP. Le dernier cours de clôture d'NRX Pharmaceuticals était de US$1,52. Au cours de la dernière année, les actions de NRX Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 1,10 à US$ 7,333.

NRX Pharmaceuticals compte actuellement 12 094 094 actions en circulation. La capitalisation boursière d'NRX Pharmaceuticals est de US$18,38 million. NRX Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -0.61.

NRXP Dernières nouvelles

Plus de nouvelles

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 PR Newswire WILMINGTON...

26 Novembre 2024
PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" PR Newswire WILMINGTON, Del., Nov. 25...

25 Novembre 2024
PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer PR Newswire WILMINGTON, Del., Nov. 18, 2024 Industry veteran with extensive experience in key areas of...

18 Novembre 2024
PR Newswire (US)

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update PR Newswire WILMINGTON, Del., Nov. 14, 2024 On track to file New Drug...

14 Novembre 2024
PR Newswire (US)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 PR Newswire WILMINGTON, Del., Nov. 13...

13 Novembre 2024
PR Newswire (US)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 PR Newswire WILMINGTON, Del., Nov. 7, 2024 WILMINGTON, Del.  , Nov. 7...

07 Novembre 2024
PR Newswire (US)

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics PR Newswire MIAMI, Oct...

30 Octobre 2024
PR Newswire (US)

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry...

26 Août 2024
PR Newswire (US)

Form 8-K - Current report

20 Août 2024
Edgar (US Regulatory)

Form 8-K - Current report

14 Août 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.335328.30252384571.18471.821.176418211.54308062CS
40.324.59016393441.221.821.153031931.41980338CS
12-0.16-9.523809523811.681.821.11918111.36618703CS
26-1.53-50.16393442623.053.11.11310511.58477862CS
52-2.31-60.31331592693.837.3331.15560324.32635233CS
156-53.58-97.241379310355.156.551.18400669.64826743CS
260-228.58-99.3394176445230.1262.41.1135432067.35944593CS

NRXP - Frequently Asked Questions (FAQ)

What is the current NRX Pharmaceuticals share price?
The current share price of NRX Pharmaceuticals is US$ 1,52
How many NRX Pharmaceuticals shares are in issue?
NRX Pharmaceuticals has 12 094 094 shares in issue
What is the market cap of NRX Pharmaceuticals?
The market capitalisation of NRX Pharmaceuticals is USD 18,38M
What is the 1 year trading range for NRX Pharmaceuticals share price?
NRX Pharmaceuticals has traded in the range of US$ 1,10 to US$ 7,333 during the past year
What is the PE ratio of NRX Pharmaceuticals?
The price to earnings ratio of NRX Pharmaceuticals is -0,61
What is the reporting currency for NRX Pharmaceuticals?
NRX Pharmaceuticals reports financial results in USD
What is the latest annual profit for NRX Pharmaceuticals?
The latest annual profit of NRX Pharmaceuticals is USD -30,16M
What is the registered address of NRX Pharmaceuticals?
The registered address for NRX Pharmaceuticals is 1201 ORANGE ST, STE 600, ONE COMMERCE CENTER, WILMINGTON, DELAWARE, 19801
What is the NRX Pharmaceuticals website address?
The website address for NRX Pharmaceuticals is www.nrxpharma.com
Which industry sector does NRX Pharmaceuticals operate in?
NRX Pharmaceuticals operates in the BLANK CHECKS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
120,01M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
76,64M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
33,95M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,61k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
120,4M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,5M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,63M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,84M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
8,58M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
5,96M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
NRXP
NRX Pharmaceuticals
AMEX
VGT
Vanguard Information Tec...
BOV
USBC34
U S Bancorp
LSE
78HJ
Liverpool 3%stk
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés